QSIVA® Receives European Regulatory Approval for Adolescent Obesity Treatment
What happened
VIVUS BV announced the positive conclusion of the European variation procedure for QSIVA® (phentermine/topiramate MR) to extend its indication to adolescents aged 12 years and older with obesity. The procedure covers 17 countries across Europe, including Hungary, Iceland, Croatia, and Finland. National medicines agencies in these countries are expected to issue final decisions within 30 days.
From manilatimes.net
Why it matters
The approval expands the availability of an evidence-based therapy for adolescent obesity, addressing a significant public health challenge in Europe. QSIVA® is already approved in these nations for weight management in adults, and the new indication broadens its market scope.
From manilatimes.net
Who's involved
- EuropeThe continent where the regulatory procedure was concluded.
- HungaryOne of the 17 countries included in the regulatory procedure.
- IcelandOne of the 17 countries included in the regulatory procedure.
- CroatiaOne of the 17 countries included in the regulatory procedure.
- FinlandOne of the 17 countries included in the regulatory procedure.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- EuropeSpeculative
The expansion of the market for obesity therapy could increase demand for related pharmaceutical products.
- Novo NordiskSpeculative
Increased competition from QSIVA® in the growing obesity treatment market might affect Novo Nordisk's revenue.
- IcelandSpeculative
The landmark approval for adolescents in Iceland could increase sales volume for QSIVA® in that segment.
- CroatiaSpeculative
The landmark approval for adolescents in Croatia could increase sales volume for QSIVA® in that segment.
- HungarySpeculative
The landmark approval for adolescents in Hungary could increase sales volume for QSIVA® in that segment.
- FinlandSpeculative
The landmark approval for adolescents in Finland could increase sales volume for QSIVA® in that segment.
Possible ripples
Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.- Increased competition from QSIVA may challenge Novo Nordisk's market positionIncreased competition from QSIVA may challenge Novo Nordisk's market positionPossible
- QSIVA's expanded approval may reshape EEA drug market accessThe expansion of QSIVA's indication could deepen regulatory harmonization within the EEAPossible